BRAF and cancer: And lastly, secreted WNT5A (as opposed to WNT3A) has been shown to negatively regulate WNT/β-catenin signaling in several cancer types, including in a subgroup of melanoma patients exhibiting acquired resistance to BRAF-inhibition [19].